statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Apogee Therapeutics Inc. APGE, a clinical-stage company, is focused on developing novel therapies for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease...

Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why

Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to...

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4R  Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

Apogee Therapeutics, Inc. (NASDAQ:APGE  Get Free Report) rose 6% during trading on Friday . The company traded as high as $71.75 and last traded at $70.50. Approximately 222,641 shares traded...

Apogee Therapeutics (NASDAQ:APGE) Stock Price Up 6%

Apogee Therapeutics, Inc. (NASDAQ:APGE  Get Free Report) has been given a consensus recommendation of Buy by the seven ratings firms that are presently covering the firm...

Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Average Rating of "Buy" by Analysts

SAN FRANCISCO, Calif. and WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated...

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million

Wedbush reaffirmed their outperform rating on shares of Apogee Therapeutics (NASDAQ:APGE  Free Report) in a report published on Tuesday morning, RTT News reports. The brokerage currently has a...

Apogee Therapeutics (NASDAQ:APGE) Earns Outperform Rating from Wedbush

Apogee Therapeutics (NASDAQ:APGE  Free Report) had its target price upped by Guggenheim from $44.00 to $91.00 in a research note issued to investors on Tuesday morning, Benzinga reports. They...

Apogee Therapeutics (NASDAQ:APGE) Given New $91.00 Price Target at Guggenheim

SAN FRANCISCO and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for...

Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

Apogee Therapeutics (NASDAQ:APGE  Free Report) had its target price hoisted by Jefferies Financial Group from $37.00 to $75.00 in a research note issued to investors on Wednesday, Benzinga...

Apogee Therapeutics (NASDAQ:APGE) Given New $75.00 Price Target at Jefferies Financial Group

Apogee Therapeutics, Inc. (NASDAQ:APGE  Get Free Report) shares traded up 6.8% during mid-day trading on Wednesday after Jefferies Financial Group raised their price target on the stock from...

Apogee Therapeutics (NASDAQ:APGE) Shares Up 6.8% on Analyst Upgrade

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.

Volume	96,401.00
52-Wk High	$72.29
52-Wk Low	$14.19

APGE Apogee Therapeutics

About

Feed

News

Sentiment

Earnings

Fundamentals